Pregnancy, Childbirth & Puerperium

Cesarean delivery: indications and VBAC counseling

Clinical Overview and When to Suspect Cesarean Delivery

— Scheduled (elective): planned ≥39+0 weeks for maternal/fetal indication or repeat CD

— Unscheduled non-emergent: labor arrest, failed induction

— Emergent (crash): cord prolapse, uterine rupture, placental abruption with non-reassuring fetal heart tracing, prolonged bradycardia

— Prior classical (vertical) uterine incision, prior T-incision, prior full-thickness myomectomy

— Active genital HSV lesions or prodrome at labor

— Untreated HIV with viral load >1000 copies/mL

— Complete or partial placenta previa, vasa previa, suspected placenta accreta spectrum

— Obstructive pelvic mass, prior pelvic floor reconstruction

— Cord prolapse with viable fetus

— Non-reassuring fetal status unresponsive to intrauterine resuscitation (Category III tracing)

— Malpresentation not amenable to ECV (transverse lie, footling breech in labor)

— Conjoined twins, fetal anomalies precluding vaginal birth (large omphalocele, hydrocephalus)

Board pearl: Suspected macrosomia alone is not a sufficient indication for CD unless EFW >5000 g (non-diabetic) or >4500 g (diabetic mother) — induction for suspected macrosomia is not supported by evidence and increases CD rate

Step 3 management: When the stem says "category III tracing despite position change, O₂, IV fluid, and tocolysis discontinuation" → next step is immediate cesarean delivery, not further monitoring or fetal scalp stimulation

Cesarean delivery (CD) is surgical birth via laparotomy and hysterotomy, accounting for ~32% of US births — the most common major surgery in women

Categorized by urgency:

Absolute maternal indications:

Absolute fetal indications:

Relative indications: breech at term, multifetal gestation with non-vertex first twin, suspected macrosomia (>5000 g non-diabetic, >4500 g diabetic), maternal cardiac/neurologic conditions

Labor dystocia is the single most common indication — must meet ACOG criteria before diagnosing arrest

Presentation Patterns and Key History

— Prior uterine surgery: number, type of incision (low transverse vs classical vs unknown), indication, year, interdelivery interval

— Number of prior CDs (>2 increases accreta risk substantially when previa present)

— Prior VBAC success or failed TOLAC

— Placentation on imaging: previa, low-lying placenta, suspected accreta features

— Maternal comorbidities: cardiac disease (NYHA III–IV), pulmonary hypertension, recent CVA, aneurysm

— Labor arrest: cervical dilation plateau ≥4 h with adequate contractions (≥200 MVU) in active phase (≥6 cm); ≥6 h with inadequate contractions

— Second-stage arrest: ≥3 h pushing in nullipara (≥4 h with epidural), ≥2 h in multipara (≥3 h with epidural)

— Failed operative vaginal delivery attempt

— Failed induction: oxytocin ≥12–18 h after membrane rupture without active phase

— Sudden severe abdominal pain, loss of station, vaginal bleeding → uterine rupture or abruption

— Painless bright red bleeding in third trimester → previa

— Rupture of membranes followed by fetal bradycardia → cord prolapse

— Active HSV prodrome (tingling, burning) at labor onset

— Prior incision type (must be low transverse or low vertical not extending to fundus)

— Number of prior CDs (one or two prior low transverse generally eligible)

— Interdelivery interval (<18 months ↑ rupture risk)

— Reason for prior CD (non-recurring like breech improves success)

Key distinction: "Failed induction" requires oxytocin and ruptured membranes for at least 12–18 h before diagnosing — calling it earlier overestimates CD necessity and is a common Step 3 distractor

Step 3 vignettes frame the CD decision at one of three classic decision points: antepartum planning, intrapartum arrest, or acute fetal compromise

Antepartum planning history:

Intrapartum history pointing to CD:

Acute red-flag history:

VBAC eligibility history must capture:

Physical Exam Findings and Maternal-Fetal Assessment

— Tense, board-like, exquisitely tender uterus → abruption

— Loss of fetal station with palpable fetal parts abdominally + cessation of contractions → uterine rupture

— Bandl's ring (visible constriction band between upper/lower segment) → obstructed labor, impending rupture

— Dilation, effacement, station, position, caput, molding

— Cord prolapse: pulsating cord palpable below presenting part → elevate presenting part, knee-chest or Trendelenburg, call for crash CD

— Active HSV lesions → CD regardless of duration of ROM

— Category I (normal): baseline 110–160, moderate variability, no late/variable decels — continue labor

— Category II (indeterminate): most labors; manage with intrauterine resuscitation

— Category III (abnormal): absent variability with recurrent late decels, recurrent variables, bradycardia, or sinusoidal pattern → deliver expeditiously, usually CD

— Reposition to left lateral

— 500–1000 mL IV LR bolus

— O₂ 10 L/min by non-rebreather (controversial; brief use acceptable)

— Discontinue oxytocin

— Consider terbutaline 0.25 mg SC for tachysystole

— Scalp stimulation to assess for acceleration

CCS pearl: In a CCS-style case with Category III tracing, order in this sequence: left lateral position → IV bolus → stop oxytocin → call OB/anesthesia → move to OR → cesarean delivery. Skipping the resuscitation steps loses points even when CD is ultimately indicated

Vital signs: maternal tachycardia + hypotension during labor → suspect abruption, rupture, or hemorrhage; fever ≥38°C + uterine tenderness → chorioamnionitis (relative indication if non-reassuring tracing follows)

Abdominal exam:

Sterile vaginal exam (SVE):

Fetal assessment via EFM (NICHD categories):

Intrauterine resuscitation bundle (must attempt before CD for Cat II):

Diagnostic Workup — Pre-Cesarean Labs and Imaging

— CBC: baseline H/H, platelets (need ≥70–80 K for neuraxial anesthesia)

— Type & screen for all; type & crossmatch 2 units for placenta previa, accreta, prior CDs ≥2, abruption, HELLP

— Coagulation panel (PT/INR, aPTT, fibrinogen) if abruption, HELLP, IUFD, or massive bleeding suspected; fibrinogen <200 mg/dL in pregnancy is abnormal

— Basic metabolic panel for preeclampsia/HELLP workup

— Urine protein if hypertensive

— Transabdominal + transvaginal US to confirm placental location, fetal presentation, EFW, AFI

— Doppler color flow for vasa previa (fetal vessels over internal os)

— MRI pelvis if placenta accreta spectrum (PAS) suspected on US — assess depth of invasion, parametrial/bladder involvement, surgical planning

— Loss of retroplacental clear space

— Placental lacunae ("Swiss cheese")

— Bladder wall interruption

— Increased subplacental vascularity on Doppler

Board pearl: A patient with prior CD + anterior placenta previa has ~25% accreta risk after 1 prior CD, climbing to ~40% after 2 and ~67% after ≥3 — must image with MRI and plan delivery at a center with massive transfusion, GYN-onc, IR, and ICU capability between 34+0 and 35+6 weeks

Standard pre-CD labs (scheduled or unscheduled):

Imaging:

PAS US features ("placenta previa + prior CD" demands this workup):

Fetal lung maturity testing is NOT recommended before scheduled CD — deliver based on gestational age (≥39+0 weeks for non-medically indicated repeat CD)

Group B Strep: not required pre-CD if membranes intact and no labor

Anesthesia preop: airway exam, last oral intake, NPO status (clear liquids ≤2 h, solids ≤6–8 h for elective)

Diagnostic Workup — Confirmatory and Anesthetic Evaluation

— Active phase: cervix ≥6 cm, ROM, no cervical change ≥4 h with adequate contractions (≥200 Montevideo units via IUPC) or ≥6 h with inadequate contractions despite oxytocin

— Second stage arrest: documented above (3/4/2/3 hour rule)

— Document position, station, caput, molding, suspected CPD

— Acceleration ≥15 bpm × 15 sec → reassuring, fetal pH >7.20

— No acceleration → consider expedited delivery

— Scheduled CD: spinal (preferred, single-shot bupivacaine + fentanyl + morphine)

— Unscheduled with epidural in place: top-up with 2% lidocaine + epi + bicarb

— Crash CD without neuraxial: general anesthesia with rapid sequence induction (RSI), cricoid pressure, propofol + succinylcholine

— Confirm patient ID, indication, allergies, antibiotic given, blood available

— Time-out before incision: patient, procedure, side/site, antibiotic, anticipated blood loss, equipment

— Cefazolin 2 g IV (3 g if BMI ≥30 or weight ≥120 kg) within 60 min of skin incision

— Add azithromycin 500 mg IV for laboring women or those with ROM (reduces endometritis)

— Penicillin allergy: clindamycin + gentamicin

Step 3 management: Always order antibiotic prophylaxis before skin incision, not after cord clamping — older teaching has been reversed; this is a high-yield change frequently tested

Confirmation of labor arrest (before committing to CD for dystocia) requires:

Intrauterine pressure catheter (IUPC) placement justified when external tocodynamometer inadequate (obesity, dystocia diagnosis) to quantify MVUs

Fetal scalp stimulation or vibroacoustic stimulation:

Anesthetic evaluation dictates urgency-appropriate technique:

Pre-induction checklist (Surgical Safety/WHO):

Antibiotic prophylaxis is confirmatory step before incision:

Decision Logic — TOLAC/VBAC vs Repeat Cesarean

— One or two prior low transverse cesareans

— Clinically adequate pelvis

— No other uterine scars or prior rupture

— Physician, anesthesia, and OR capable of emergency CD immediately available

— Patient counseled and consenting

— Prior classical, T-, or J-incision, or prior fundal myomectomy entering cavity

— Prior uterine rupture

— Medical/obstetric condition precluding vaginal birth (previa, vasa previa, malpresentation)

— Inability to perform emergency CD (no in-house OB/anesthesia)

— Age, BMI, race/ethnicity, prior vaginal delivery, prior VBAC, prior CD indication, current cervical exam

— Success >60–70% favors TOLAC; <50% favors repeat CD

— Spontaneous labor after 1 prior low transverse: 0.5–0.7%

— Induced labor with oxytocin: ~1%

— Induced with prostaglandins (misoprostol): 2–5% — contraindicated

— Two prior low transverse CDs: ~1.5%

— Prior classical: 4–9% (often before labor)

Key distinction: Misoprostol (PGE1) is absolutely contraindicated for cervical ripening in TOLAC due to unacceptably high rupture risk — mechanical methods (Foley balloon) or oxytocin are acceptable if induction needed

TOLAC (trial of labor after cesarean) candidate selection per ACOG:

Contraindications to TOLAC (mandate repeat CD):

VBAC success calculators (MFMU model) integrate:

Rupture risk by scenario:

Favorable VBAC predictors: prior vaginal delivery (especially prior VBAC), spontaneous labor onset, non-recurring prior CD indication (breech), age <35, BMI <30

Unfavorable: induction needed, recurrent indication (arrest of dilation, CPD), interdelivery interval <18 months, gestational age >40 weeks

Pharmacotherapy — Peri-Cesarean Medications

— Cefazolin 2 g IV (3 g if ≥120 kg), 15–60 min before skin incision

— Add azithromycin 500 mg IV over 1 hour for non-elective CD in labor or with ROM

— True β-lactam allergy: clindamycin 900 mg IV + gentamicin 5 mg/kg IV

— Redose cefazolin if surgery >4 h or EBL >1500 mL

— Oxytocin 10–40 units in 1 L LR IV infusion immediately after delivery — first-line prophylaxis

— Methylergonovine 0.2 mg IM — avoid in hypertension, preeclampsia

— Carboprost (Hemabate) 250 mcg IM q15 min, max 2 mg — avoid in asthma

— Misoprostol 800–1000 mcg rectal/sublingual — safe in asthma/HTN

— Tranexamic acid 1 g IV within 3 hours if PPH — reduces mortality

— Mechanical (SCDs) for all CD patients intraop and until ambulatory

— Pharmacologic LMWH (enoxaparin 40 mg SC daily) for high-risk: BMI ≥40, prior VTE, thrombophilia, prolonged immobility, postpartum infection

— Continue 6 weeks postpartum if high-risk

— Intrathecal/epidural morphine 0.1–0.2 mg (intrathecal) or 3 mg (epidural) — 18–24 h analgesia

— Scheduled acetaminophen 1 g q6h + NSAID (ketorolac 30 mg IV q6h × 24 h, then ibuprofen 600 mg q6h)

— Opioids PRN for breakthrough only — minimize for opioid-stewardship

Board pearl: TXA within 3 hours of PPH reduces death from bleeding (WOMAN trial). After 3 hours it's ineffective and not recommended — time-sensitive intervention

Antibiotic prophylaxis (single most important infection-prevention step):

Uterotonics (post-delivery atony prevention/treatment, in order):

VTE prophylaxis (CD doubles VTE risk vs vaginal):

Analgesia (multimodal opioid-sparing):

GBS prophylaxis NOT needed if CD with intact membranes before labor

Procedural Details — Cesarean Technique and Intraoperative Decisions

— Pfannenstiel (low transverse): better cosmesis, less dehiscence, standard

— Vertical midline: rapid entry for crash CD, morbid obesity, prior vertical scar, suspected accreta

— Low transverse (Kerr): preferred, lowest rupture risk (~0.5%), VBAC-eligible

— Low vertical (Krönig): used for poorly developed lower segment, transverse lie, preterm; VBAC eligibility debated but acceptable per ACOG

— Classical (vertical upper segment): emergencies, transverse lie with back down, previa with anterior implantation, accreta, fetal anomaly; rupture risk 4–9%, contraindicates future TOLAC

— Vertex: flex and elevate, fundal pressure

— Breech: extract feet first

— Transverse lie: internal version or vertical hysterotomy

— Double-layer closure reduces uterine dehiscence and improves subsequent VBAC safety (vs single-layer)

— Locking first layer, imbricating second

— Bladder flap creation optional (no benefit in elective)

— Peritoneal closure not required (no benefit, may ↑ adhesions)

— Subcutaneous closure if depth ≥2 cm reduces wound separation

— Skin: subcuticular suture preferred over staples (less wound morbidity)

CCS pearl: When prior CD type is "unknown," counsel that VBAC may still be offered if the prior CD was for a non-recurring indication and the patient is otherwise a good candidate — "unknown scar" is NOT an automatic contraindication to TOLAC

Skin incision:

Uterine incision (clinically critical — defines future VBAC eligibility):

Delivery sequence:

Placenta: spontaneous expulsion with cord traction + oxytocin preferred over manual extraction (manual ↑ endometritis)

Uterine closure:

Adjunctive steps:

Placenta accreta spectrum: planned cesarean hysterectomy at 34+0 to 35+6 weeks in tertiary center with MTP, GYN-onc, IR (prophylactic balloon catheters optional), ICU

Special Populations — Renal, Hepatic, and Medical Comorbidities

— Dose-adjust cefazolin if CrCl <30 (q12h instead of q8h post-op if extended course)

— Avoid NSAIDs if CrCl <60 or active preeclampsia — use acetaminophen + opioid

— Increased VTE risk → consider extended LMWH

— Magnesium for preeclampsia: reduce dose if Cr >1.0 (load 4 g, maintenance 1 g/h vs standard 2 g/h)

— Coagulopathy mandates fibrinogen >200, platelets >70K before neuraxial; consider cryoprecipitate, FFP, platelets preop

— Avoid acetaminophen >2 g/day in significant hepatic dysfunction

— AFLP is a delivery indication regardless of gestational age

— Severe AS, pulmonary HTN, Eisenmenger, Marfan with aortic root >45 mm, peripartum cardiomyopathy with EF <30% → CD often preferred to avoid Valsalva

— Slow titrated epidural preferred over single-shot spinal (avoid sudden preload drop)

— Invasive monitoring (arterial line ± PA catheter) per case

— Cefazolin 3 g dose

— Vertical skin incision or supraumbilical transverse may be needed

— Extended LMWH prophylaxis × 6 weeks postpartum

— Higher wound complication, anesthesia difficulty, OR time

— Tight glycemic control intraop (target 100–140 mg/dL); insulin drip if needed

— Pre-CD steroids for fetal lung maturity if <37 weeks increase maternal glucose — anticipate

Step 3 management: In a patient with severe pulmonary HTN, both vaginal and cesarean delivery carry high mortality (~30–50%) — multidisciplinary delivery planning at a tertiary center with cardiac anesthesia is the right next step, not a unilateral CD decision

Chronic kidney disease:

Hepatic disease (cholestasis, HELLP, AFLP):

Cardiac disease (modified WHO class III–IV):

Obesity (BMI ≥40):

Diabetes:

Anticoagulation: hold therapeutic LMWH ≥24 h, prophylactic ≥12 h, before neuraxial; warfarin requires reversal and bridging plan

Special Populations — Adolescents, Advanced Maternal Age, Multiples, Preterm

— No CD indication based on age alone; pelvic capacity usually adequate

— Higher rates of preeclampsia, preterm, and operative delivery — counsel on TOLAC eligibility for future pregnancies

— Higher CD rate but age alone is not an indication

— ≥40 with chronic HTN, prior CD, IVF pregnancy → individualized

— Di-di or mono-di twins, twin A vertex: vaginal trial reasonable regardless of twin B presentation (per Twin Birth Study), provided experienced operator

— Twin A non-vertex: CD

— Mono-mono twins: scheduled CD at 32–34 weeks

— Triplets or higher: typically CD

— Term Breech Trial showed reduced perinatal mortality with planned CD → standard

— Offer external cephalic version (ECV) at 36–37 weeks (success ~60%); CD if ECV fails or contraindicated

— ECV contraindications: previa, prior classical, non-reassuring tracing, multiple gestation with twin A breech

— Antenatal corticosteroids (betamethasone 12 mg IM × 2, 24 h apart) for 24+0 to 33+6 weeks; consider 34+0–36+6 if no prior course

— Magnesium sulfate for neuroprotection if <32 weeks (4–6 g load, 1–2 g/h × 12–24 h)

— GBS prophylaxis if labor and unknown GBS

— Low transverse incision often not feasible at <28 weeks → low vertical may be required, affecting future VBAC counseling

Key distinction: External cephalic version success ~60% — offer to every term breech without contraindication; failing to offer ECV is a documentation/counseling miss commonly tested

Adolescent pregnancy:

Advanced maternal age (≥35):

Multifetal gestation:

Breech presentation at term:

Preterm delivery (<37 weeks):

Periviable (22+0–25+6): CD reserved for maternal indications or with parental request after counseling on neonatal outcomes — shared decision making essential

Complications and Adverse Outcomes

— Hemorrhage (EBL >1000 mL): atony (most common), lacerations, placenta accreta, uterine rupture

— Bladder injury (~0.3%): higher with repeat CD, accreta, prior pelvic surgery

— Bowel injury (<0.1%): adhesions from prior surgery

— Ureteral injury (~0.03%): cystotomy/extension into broad ligament

— Hysterectomy (~0.5%, much higher with accreta — up to 50%+)

— Endometritis (5–10× more common than after vaginal): fever, fundal tenderness, foul lochia → clindamycin + gentamicin IV until afebrile 24–48 h

— Wound infection/separation: 3–5%, higher with obesity, diabetes, chorio

— Postpartum hemorrhage: 4–6%

— VTE: DVT/PE risk 4× vaginal delivery

— Ileus, atelectasis, UTI (from Foley)

— Adhesions: progressive with each CD

— Niche/isthmocele (cesarean scar defect): abnormal bleeding, dysmenorrhea, infertility

— Cesarean scar ectopic in next pregnancy

— Placenta accreta spectrum in subsequent pregnancies — risk climbs steeply with CD number

— Transient tachypnea of newborn (TTN): especially CD before labor; lung fluid retention

— Iatrogenic prematurity if delivered before 39+0 without indication — RDS, NICU admission

— Lower neonatal microbiome diversity, possibly higher asthma/atopy risk

Board pearl: Endometritis after CD = polymicrobial; treat with clindamycin 900 mg IV q8h + gentamicin 1.5 mg/kg q8h (or 5 mg/kg daily) until afebrile 24–48 h; no oral step-down needed if uncomplicated

Intraoperative complications:

Anesthetic: high spinal, post-dural puncture headache, failed intubation, aspiration

Postoperative (early):

Postoperative (late):

Neonatal:

Maternal mortality: 3–4× higher with CD vs vaginal (much from underlying indication, but procedure itself contributes)

When to Escalate — Intraoperative and Postoperative Triage

— EBL >1500 mL or ongoing hemorrhage despite uterotonics → activate massive transfusion protocol (1:1:1 RBC:FFP:platelets), call second OB, GYN-onc, IR, anesthesia

— B-Lynch suture, intrauterine balloon (Bakri), uterine artery ligation as stepwise atony management

— Hysterectomy if refractory; do not delay in accreta

— Bladder/bowel injury → intraoperative urology/general surgery consult and primary repair

— Hypotension + tachycardia + falling H/H → return to OR; image with CT/US if stable, but unstable = exploration

— Persistent fever despite broad-spectrum antibiotics 48–72 h:

— Septic pelvic thrombophlebitis (diagnosis of exclusion) → add heparin

— Pelvic abscess → CT, drainage

— Retained products → US, possible D&C

— Respiratory distress post-op: rule out PE (CTA), pulmonary edema (especially with magnesium + preeclampsia), atelectasis

— Oliguria <0.5 mL/kg/h: assess volume, rule out preeclampsia/HELLP progression, hemorrhage

— Vasopressor need, intubation, massive transfusion, eclampsia with status, AKI requiring CRRT, severe sepsis

— Anesthesia (always)

— NICU (preterm, fetal distress, meconium, maternal diabetes, chorio)

— GYN-onc/IR (suspected accreta)

— Hematology (HELLP, DIC, refractory bleeding)

— MFM (complex obstetric)

CCS pearl: In a postpartum CD patient with persistent fevers, normal pelvic exam, no abscess on CT, and negative blood cultures, the answer is empirically anticoagulate for septic pelvic thrombophlebitis — defervescence within 48 h confirms the diagnosis

Intraoperative escalation triggers:

Postoperative escalation:

ICU transfer criteria:

Consults to anticipate (CCS-style ordering):

Key Differentials — Obstetric Causes of CD vs Alternatives

— Before diagnosing arrest, ensure adequate MVUs ≥200 with IUPC and ROM

— If inadequate, augment with oxytocin rather than proceed to CD

— Cat II with mild variables → intrauterine resuscitation, scalp stimulation

— Persistent late decels with absent variability = Cat III → CD

— Offer ECV before scheduled CD

— EFW <5000 g (non-diabetic) — vaginal trial appropriate

— EFW ≥4500 g + diabetes — counsel CD

— Latent phase >20 h nullip / >14 h multip alone is NOT failed induction — must have adequate uterine activity, ROM, and ≥12–18 h oxytocin without active phase

— Placental edge <2 cm from os but not covering → can attempt vaginal delivery with caution

— Covering os → CD mandatory

— Active lesion or prodrome at labor → CD

— Prior HSV without active lesion → vaginal delivery acceptable; suppressive acyclovir from 36 weeks reduces recurrence

— Twin A vertex regardless of twin B presentation → vaginal trial possible

— Twin A non-vertex → CD

Key distinction: A placental edge <2 cm from internal os at term is "low-lying" and usually managed by planned vaginal delivery with cesarean readiness; only a placenta covering the os is a true previa requiring CD

Many CD indications have alternatives on the same obstetric spectrum:

Labor dystocia vs inadequate contractions:

Suspected fetal distress vs truly non-reassuring tracing:

Breech vs vertex achievable via ECV:

Macrosomia concern vs shoulder dystocia risk only:

Failed induction vs prolonged latent phase:

Previa vs low-lying placenta:

HSV considerations:

Twin gestation considerations:

Key Differentials — Non-Obstetric Pathology Mimicking CD Indications

— Appendicitis: RLQ/RUQ pain (location shifts upward with gestational age), leukocytosis (normal pregnancy can have WBC up to 15K), MRI preferred over CT — needs surgery, not CD

— Cholecystitis: RUQ, US-confirmed — cholecystectomy, not CD

— Nephrolithiasis: flank pain, hematuria — US/MR urogram; manage conservatively

— Pancreatitis: epigastric, elevated lipase

— Severe preeclampsia/eclampsia: deliver at ≥34 weeks regardless of route; CD only for obstetric indication, not for preeclampsia alone

— HELLP: same — induce if cervix favorable, CD if maternal/fetal compromise

— Treat with ampicillin + gentamicin + clindamycin (if CD); chorio alone is NOT a CD indication — augment labor unless other obstetric reason

— Abruption (painful, tender uterus, fetal distress)

— Previa (painless, bright red)

— Vasa previa (fetal bleeding with ROM, fetal bradycardia)

— Bloody show (mucous-streaked, normal)

— Uterine rupture (sudden pain, loss of station, fetal bradycardia, hemodynamic collapse)

— Peripartum cardiomyopathy presenting as dyspnea — echo before assuming PE

— PE — CTA or V/Q

— Amniotic fluid embolism: sudden hypotension, hypoxia, DIC in labor — supportive, emergent CD if undelivered

Board pearl: Chorioamnionitis alone is not an indication for cesarean — the goal is expeditious delivery by the most appropriate route, with broad-spectrum antibiotics and antipyretics; CD reserved for usual obstetric indications

Acute abdominal pain in pregnancy can mimic obstetric emergencies:

Hypertensive emergencies mimicking labor:

Sepsis/chorio: high fever, fundal tenderness, fetal tachycardia

Vaginal bleeding differential:

Cardiac mimics:

Secondary Prevention and Postpartum Discharge Plan

— Acetaminophen 1 g PO q6h scheduled × 1–2 weeks

— Ibuprofen 600 mg PO q6h (renal function permitting) × 1–2 weeks

— Oxycodone 5 mg q4–6h PRN — limit to 10–20 tablets (opioid stewardship)

— Docusate 100 mg BID (opioid + iron + post-op ileus)

— Iron if Hgb <10 g/dL

— Enoxaparin 40 mg SC daily × 6 weeks if BMI ≥40, prior VTE, thrombophilia

— Interdelivery interval ≥18 months strongly advised for future TOLAC candidates

— Document tubal sterilization consent (Medicaid requires ≥30 days before)

— Keep clean and dry, no soaking baths × 2 weeks

— Watch for erythema, drainage, dehiscence, fever

— No heavy lifting (>10 lb) × 6 weeks

— No driving until off opioids and can brake comfortably (usually 1–2 weeks)

— No intercourse, tampons, douching × 6 weeks

— Document incision type in operative note and discharge summary

— Provide written summary patient can carry to next provider

— Discuss eligibility, success rates, risks

Step 3 management: Document uterine incision type explicitly in op note and discharge paperwork — "unknown scar" complicates future VBAC counseling and is a real-world safety issue tested via documentation/transitions-of-care vignettes

Discharge timing: typical CD discharge POD 2–4 once tolerating diet, ambulating, voiding, pain controlled on oral meds, afebrile

Discharge medications:

Contraception counseling before discharge (LARC, sterilization, progestin-only methods compatible with breastfeeding immediately; combined OCPs after 4–6 weeks if no VTE risk):

Wound care:

Activity:

VBAC counseling for next pregnancy at discharge:

Vaccinations: Tdap if not received in pregnancy, MMR/varicella if non-immune, influenza/COVID if seasonal, RhoGAM if Rh-negative

Follow-Up, Monitoring, and Counseling

— First contact within 3 weeks (phone, telehealth, or in person) — assess pain, mood, bleeding, breastfeeding, wound

— Comprehensive visit by 12 weeks — full physical, contraception, chronic disease optimization, transition to primary care

— Earlier visit (1–2 weeks) if preeclampsia, GDM, wound concerns, mental health

— BP check within 3–7 days if any hypertensive disorder of pregnancy (preeclampsia, gestational HTN); 72 hours if severe features — postpartum preeclampsia and stroke peak in first 1–2 weeks

— Glucose tolerance test at 4–12 weeks postpartum for GDM history (2-h 75-g OGTT)

— Hgb at 6 weeks if postpartum anemia treated

— Wound exam at 1–2 weeks if obese, diabetic, or any drainage

— CD does not preclude breastfeeding; encourage skin-to-skin in OR if stable

— Most CD analgesics (acetaminophen, ibuprofen, oxycodone short-course) compatible

— Edinburgh Postnatal Depression Scale (EPDS) at every postpartum visit

— Higher PPD risk after emergent/unplanned CD — debrief, validate

— CD reduces but does not eliminate pelvic floor dysfunction; refer to pelvic PT for persistent symptoms

— Recommend interdelivery interval ≥18 months to reduce rupture risk

— Provide individualized VBAC success probability

— Discuss escalating accreta risk with each subsequent CD

— Address contraceptive plan to achieve spacing

Board pearl: Postpartum hypertension and stroke peak 7–10 days after delivery — every patient with HDP needs a BP check within 3–7 days. This early follow-up is now a quality measure and frequently tested

Postpartum visit schedule (ACOG redesigned postpartum care):

Monitoring parameters:

Breastfeeding support:

Mental health screening:

Pelvic floor:

Counseling for next pregnancy:

Ethical, Legal, and Patient Safety Considerations

— Discuss indications, risks (hemorrhage, infection, VTE, bladder/bowel injury, hysterectomy, future accreta), benefits, alternatives (TOLAC, vaginal delivery)

— Document in chart with specific risks and patient questions

— Consent obtained before sedation/neuraxial anesthesia when possible

— Ethically permitted with thorough counseling on long-term risks

— Should not be performed before 39+0 weeks without medical indication

— Counsel about cumulative accreta risk if desiring large family

— Rupture risk (~0.5–0.7% with one prior LTCS)

— Maternal/neonatal consequences if rupture occurs

— Availability of emergency CD

— Success probability

— Document signed counseling — frequent malpractice trigger

— A competent adult patient may refuse cesarean even when fetal life is at risk

— Court-ordered CD is ethically condemned by ACOG; involve ethics committee, social work, additional counseling

— Document capacity assessment

— Medicaid (Title XIX) consent must be signed ≥30 days and ≤180 days before the procedure; preterm delivery exception allows ≥72 h if signed ≥30 days before EDC

— Failure to follow rules = no reimbursement and ethical concern about coercion

— Operative incision type must be communicated to next provider — single biggest VBAC-counseling failure

— Provide patient-held documentation

— Time-out before incision (universal protocol)

— Closed-loop counts (sponge, needle, instrument) — retained foreign body is a sentinel event

— Antibiotic timing audit

Step 3 management: A laboring patient with capacity who refuses cesarean for a Category III tracing — the answer is continued support, repeated counseling, ethics consult, documentation — NOT court order or coerced surgery

Informed consent for CD:

CD on maternal request (CDMR):

TOLAC informed consent essentials:

Refusal of CD:

Maternal-fetal conflict: respect maternal autonomy while educating thoroughly

Sterilization at time of CD:

Transitions of care:

Surgical safety:

High-Yield Associations and Rapid-Fire Facts

Board pearl: Memorize the accreta-risk-by-CD-number sequence (3%, 11%, 40%, 61%, 67% with previa) — directly tested and drives counseling about completing childbearing

CD rate in US: ~32% of all births; nulliparous term singleton vertex (NTSV) rate is the key quality metric (~26%, target <23.6%)

Most common indication for primary CD: labor dystocia (arrest of dilation/descent)

Most common indication for repeat CD: prior CD

TOLAC rupture risk: 0.5–0.7% (1 prior LTCS), VBAC success 60–80%

Misoprostol absolutely contraindicated for cervical ripening with prior CD

Antibiotic timing: cefazolin 2 g (3 g if ≥120 kg) within 60 min before skin incision + azithromycin if laboring/ROM

Endometritis treatment: clindamycin + gentamicin (covers anaerobes + GBS + GNR)

Uterotonic ladder: oxytocin → methylergonovine (avoid in HTN) → carboprost (avoid in asthma) → misoprostol → TXA

VBAC contraindications: prior classical, T, J, full-thickness myomectomy, prior rupture

Placenta accreta: deliver 34+0–35+6 weeks with planned hysterectomy

Accreta risk with previa + prior CDs: 3% (0), 11% (1), 40% (2), 61% (3), 67% (≥4)

Elective CD timing: ≥39+0 weeks unless medical indication

Antenatal steroids window: 24+0–33+6 (consider 34+0–36+6 if no prior course and preterm)

Magnesium neuroprotection: <32 weeks

GBS prophylaxis NOT needed for scheduled CD with intact membranes before labor

Double-layer uterine closure preferred for future VBAC eligibility

Term Breech Trial → planned CD for breech

Twin Birth Study → vaginal trial OK if Twin A vertex

Interdelivery interval <18 months ↑ rupture risk

VTE prophylaxis: SCDs for all; LMWH for high-risk × 6 weeks

TXA: within 3 hours of PPH

Postpartum BP check within 3–7 days for HDP

Postpartum visit: within 3 weeks then comprehensive by 12 weeks

Board Question Stem Patterns

Key distinction: Step 3 frequently tests decision sequencing — intrauterine resuscitation steps before CD, antibiotic before incision, ECV offer before scheduled CD for breech, ripening method choice for TOLAC induction

Stem 1 — Labor arrest: G1P0 at 41 weeks, 6 cm × 4 h with IUPC 220 MVU, no cervical change, fetal tracing Category I → answer is cesarean for active phase arrest, not more oxytocin

Stem 2 — VBAC candidate selection: G3P2 with two prior low transverse CDs, current pregnancy at 38 weeks vertex, no other contraindications → TOLAC is acceptable with counseling

Stem 3 — Prior classical: prior CD at 26 weeks for transverse lie with vertical hysterotomy → scheduled repeat CD at 36–37 weeks; TOLAC contraindicated

Stem 4 — Cord prolapse: ROM followed by fetal bradycardia and palpable pulsating cord → elevate presenting part, knee-chest position, emergent CD

Stem 5 — Category III tracing: persistent late decels, absent variability, failed intrauterine resuscitation → emergent cesarean

Stem 6 — Antibiotic timing: nurse asks when to give cefazolin → within 60 minutes BEFORE skin incision

Stem 7 — Postpartum fever POD#3 after CD: fundal tenderness, foul lochia → endometritis, treat with clindamycin + gentamicin

Stem 8 — Refractory postpartum fevers: negative cultures, normal CT, no abscess → septic pelvic thrombophlebitis, add heparin

Stem 9 — Suspected accreta: previa with 2 prior CDs, lacunae on US → MRI, plan delivery 34–35 weeks at tertiary center with hysterectomy team

Stem 10 — TOLAC induction: patient with 1 prior CD, post-dates, unfavorable cervix; question asks about ripening agent → mechanical (Foley balloon) or oxytocin; misoprostol contraindicated

Stem 11 — Breech at term: counsel for ECV at 37 weeks, scheduled CD if fails

Stem 12 — HSV at labor: active lesion or prodrome → CD; suppressive acyclovir from 36 weeks reduces this

Stem 13 — Maternal refusal of CD: competent patient refuses despite Cat III → ethics, counseling, documentation, not court order

One-Line Recap

Cesarean delivery is reserved for evidence-based maternal or fetal indications, performed with cefazolin prophylaxis before incision and a low transverse uterine incision when feasible; TOLAC is safe and recommended for most women with one or two prior low transverse cesareans after careful counseling on the 0.5–0.7% rupture risk and 60–80% success rate.

Board pearl: When in doubt on a Step 3 stem, ask: (1) Is there a true indication? (2) Have intrauterine resuscitation and labor optimization been attempted? (3) Has the patient been counseled and consented? (4) Is the timing ≥39+0 weeks for non-medically indicated cases? (5) Has incision type been documented for the next pregnancy?

Pre-incision essentials: cefazolin 2–3 g (+ azithromycin if laboring/ROM) within 60 min, time-out, type & screen, neuraxial preferred

VBAC eligibility: prior low transverse incision(s), no prior rupture or classical scar, immediate emergency CD capability, informed consent — misoprostol is absolutely contraindicated for cervical ripening

Cumulative risk awareness: accreta risk with previa climbs from 3% (no prior CD) to ~67% (≥4 prior CDs) — counsel patients planning large families about completing childbearing

Postpartum priorities: VTE prophylaxis (SCDs ± LMWH × 6 weeks if high-risk), multimodal opioid-sparing analgesia, BP check within 3–7 days if HDP, comprehensive postpartum visit by 12 weeks, document uterine incision type explicitly for future VBAC counseling

Ethical anchor: a competent patient may refuse CD even when fetal life is at risk — respond with counseling, support, ethics consultation, and documentation rather than coercion or court order